Neurotransmitter-induced hypothalamic-pituitary-adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats: in vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin-releasing hormone.
The susceptibility of female Lewis (LEW/N) rats to the development of streptococcal cell wall (SCW)-induced arthritis and other autoimmune phenomena is associated with the inability of their hypothalamic-pituitary-adrenal (HPA) axis to adequately respond to inflammatory stimuli. In contrast, resistance to the development of SCW-induced arthritis and other inflammatory autoimmune manifestations in histocompatible female Fischer rats (F344/N) is related to their intact HPA axis response to inflammatory mediators. To evaluate the mechanism and the specificity of the HPA axis defect in LEW/N rats, we examined the ability of three major excitatory neurotransmitter systems to activate the HPA axis in both Lewis and Fisher rats. The responsiveness of plasma ACTH and corticosterone to the cholinergic muscarinic receptor agonist arecoline, the alpha 1-adrenergic receptor agonist methoxamine and the serotonin (5-HT) type 2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane were significantly blunted and/or abolished in LEW/N compared to F344/N rats. To localize the HPA axis defect to the hypothalamic CRH neuron, we evaluated the ability of explanted hypothalami from the two strains to secrete immunoreactive CRH in vitro, in response to acetylcholine (ACh), norepinephrine (NE), 5-HT and the 5-HT agonist quipazine. LEW/N hypothalami released less immunoreactive CRH (iCRH) in response to ACh, NE, 5-HT and quipazine than F344/N hypothalami. The dose-response curves of these compounds in the former were shifted to the right and/or abolished, suggesting decreased sensitivity of LEW/N hypothalami to these neurotransmitters.(ABSTRACT TRUNCATED AT 250 WORDS)
Calogero
A E
AE
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, Md 20892.
Sternberg
E M
EM
Bagdy
G
G
Smith
C
C
Bernardini
R
R
Aksentijevich
S
S
Wilder
R L
RL
Gold
P W
PW
Chrousos
G P
GP
D000311:Adrenal Glands / Q000187:drug effects / Q000503:physiopathology*; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D001115:Arecoline / Q000494:pharmacology; D003345:Corticosterone / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism*; D005260:Female; D007031:Hypothalamus / Q000187:drug effects / Q000503:physiopathology*; D007249:Inflammation / Q000503:physiopathology*; D008729:Methoxamine / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects / Q000503:physiopathology*; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism
D000662:Amphetamines; D018377:Neurotransmitter Agents; D011942:Receptors, Adrenergic, alpha; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin; D001115:Arecoline; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D008729:Methoxamine; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine; D003345:Corticosterone